rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Black Diamond Therapeutics, Inc.

BDTX · Nasdaq

Health CareBiotechnologyNot moving yet

BDTX stood above a rising 150-day average in 6 of the last 52 weekly readings, and has been out of that trend for the last 46 weeks. It is 20.4% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 46
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
92 (-1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 6 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$11.6M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders92-1 on the quarter
New · exited31 · 32
Reported value$52.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
NEA Management Company, LLCunchanged · filed 14 Aug 20264,448,757$8.2M00.0%
BlackRock, Inc.added · filed 7 Aug 20263,917,088$7.2M+2,810,248+253.9%
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 20262,125,270$3.9M+2,125,270
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 20261,962,394$3.6M+318,647+19.4%
Defilade Capital Management, L.P.new · filed 14 Aug 20261,674,999$3.1M+1,674,999
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 20261,365,384$2.5M+63,720+4.9%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,218,171$2.3M+681,596+127.0%
Connor, Clark & Lunn Investment Management Ltd.added · filed 13 Aug 20261,092,885$2.0M+34,488+3.3%
AWM Investment Company, Inc.added · filed 14 Aug 20261,000,000$1.9M+475,000+90.5%
MARSHALL WACE, LLPadded · filed 13 Aug 2026896,602$1.7M+60,336+7.2%
31 Mar 2023 – 30 Jun 2026
416895Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Ali Behbahani Company insiderDirector · last 18 Sep 20262 · 0
Prakash Raman Company insiderDirector · last 18 Sep 20260 · 0
Garry E. Menzel Company insiderDirector · last 26 Jun 20260 · 0
Kapil Dhingra Company insiderDirector · last 26 Jun 20260 · 0
Samarth Kulkarni Company insiderDirector · last 26 Jun 20260 · 0
Shannon Campbell Company insiderDirector · last 26 Jun 20260 · 0
Brent Hatzis-Schoch Company insiderSEE REMARKS · last 21 Jan 20261 · 9
Elizabeth Buck Company insiderCHIEF SCIENTIFIC OFFICER · last 21 Jan 20260 · 0
Erika Jones Company insiderSEE REMARKS · last 21 Jan 20260 · 0
Mark A. Velleca Company insiderPRESIDENT & CEO · last 21 Jan 20260 · 0
Sergey Yurasov Company insiderCHIEF MEDICAL OFFICER · last 21 Jan 20260 · 0
Growth N. V. Biotech Company insider10% owner · last 19 Mar 20259 · 1

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 202517.9%
Return on capital employedFY 2025 · to 31 Dec 20259.8%
Cash conversionFY 2025 · to 31 Dec 2025132%
Research spendFY 2025 · to 31 Dec 202547.9%
Share count trendFY 2025 · to 11 Mar 20260.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$21.0M

Analyst forecasts

No analyst forecasts yet.